Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laplante, M.
Right arrow Articles by Deshaies, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laplante, M.
Right arrow Articles by Deshaies, Y.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 52:291-299, 2003
© 2003 by the American Diabetes Association, Inc.

PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity

Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion

Mathieu Laplante1, Henrike Sell1, Karen L. MacNaul2, Denis Richard1, Joel P. Berger2, and Yves Deshaies1

1 Department of Anatomy and Physiology, Laval Hospital Research Center, School of Medicine, Laval University, Québec, Canada
2 Department of Metabolic Disorders, Merck Research Laboratories, Rahway, New Jersey

This study sought to determine whether the adipose depot-specific (subcutaneous [SF] vs. visceral [VF]) action of peroxisome proliferator-activated receptor-{gamma} (PPAR-{gamma}) agonists on fat deposition extends to the expression of lipoprotein lipase (LPL) and other key adipose lipid metabolism genes, and whether changes in LPL impact triglyceridemia. Rats were fed a standard diet or an obesity-promoting diet for 3 weeks, with or without treatment with COOH, a nonthiazolidinedione PPAR-{gamma} agonist. Treatment effects were essentially similar in both dietary cohorts. COOH did not affect weight gain, but increased SF (inguinal) fat mass twofold and reduced VF (retroperitoneal) accretion by half. Corresponding depot-specific alterations were observed in mRNA levels of the glucocorticoid-activating enzyme 11ß-hydroxysteroid dehydrogenase 1 (11ß-HSD-1) and the thermogenic modulator uncoupling protein 1 (UCP-1). COOH increased brown adipose tissue (BAT) weight and LPL availability by five- to eightfold. In rats refed standard diet after a 24-h fast, COOH reduced the insulin excursion by half. The agonist increased SF LPL activity and mRNA levels, but had no effect on VF LPL. The two- to threefold postprandial increase in plasma triglycerides (TGs) was abrogated in COOH-treated rats, likely in part because of increased LPL in SF and BAT. Thus PPAR-{gamma} agonist treatment had a powerful, site-specific effect on adipose metabolism and lipid deposition, and greatly impacted the postprandial handling of TG-rich lipoproteins. These depot-specific effects may be mediated by differential regulation of key metabolic genes, including LPL, 11ß-HSD-1, and UCP-1.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
B. Mlinar, M. Pfeifer, E. Vrtacnik-Bokal, M. Jensterle, and J. Marc
Decreased lipin 1{beta} expression in visceral adipose tissue is associated with insulin resistance in polycystic ovary syndrome
Eur. J. Endocrinol., December 1, 2008; 159(6): 833 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Petrovic, I. G. Shabalina, J. A. Timmons, B. Cannon, and J. Nedergaard
Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPAR{gamma} agonist
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E287 - E296.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. Hemmeryckx, R. van Bree, B. Van Hoef, L. Vercruysse, H. R. Lijnen, and J. Verhaeghe
Adverse Adipose Phenotype and Hyperinsulinemia in Gravid Mice Deficient in Placental Growth Factor
Endocrinology, May 1, 2008; 149(5): 2176 - 2183.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Sena, I. R. Rasmussen, A. R. Wende, A. P. McQueen, H. A. Theobald, N. Wilde, R. O. Pereira, S. E. Litwin, J. P. Berger, and E. D. Abel
Cardiac Hypertrophy Caused by Peroxisome Proliferator- Activated Receptor-{gamma} Agonist Treatment Occurs Independently of Changes in Myocardial Insulin Signaling
Endocrinology, December 1, 2007; 148(12): 6047 - 6053.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. J. Wake, R. H. Stimson, G. D. Tan, N. Z. M. Homer, R. Andrew, F. Karpe, and B. R. Walker
Effects of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} Agonists on 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Subcutaneous Adipose Tissue in Men
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1848 - 1856.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Berthiaume, M. Laplante, W. Festuccia, Y. Gelinas, S. Poulin, J. Lalonde, D. R. Joanisse, R. Thieringer, and Y. Deshaies
Depot-Specific Modulation of Rat Intraabdominal Adipose Tissue Lipid Metabolism by Pharmacological Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Type 1
Endocrinology, May 1, 2007; 148(5): 2391 - 2397.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
I. Bogacka, T. W. Gettys, L. de Jonge, T. Nguyen, J. M. Smith, H. Xie, F. Greenway, and S. R. Smith
The Effect of {beta}-Adrenergic and Peroxisome Proliferator-Activated Receptor-{gamma} Stimulation on Target Genes Related to Lipid Metabolism in Human Subcutaneous Adipose Tissue
Diabetes Care, May 1, 2007; 30(5): 1179 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, and Y. Deshaies
Involvement of adipose tissues in the early hypolipidemic action of PPAR{gamma} agonism in the rat
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1408 - R1417.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. E. Trujillo and P. E. Scherer
Adipose Tissue-Derived Factors: Impact on Health and Disease
Endocr. Rev., December 1, 2006; 27(7): 762 - 778.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al.
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
I J Bujalska, M Quinkler, J W Tomlinson, C T Montague, D M Smith, and P M Stewart
Expression profiling of 11{beta}-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes.
J. Mol. Endocrinol., October 1, 2006; 37(2): 327 - 340.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, J. P. Berger, and Y. Deshaies
Mechanisms of the Depot Specificity of Peroxisome Proliferator-Activated Receptor {gamma} Action on Adipose Tissue Metabolism.
Diabetes, October 1, 2006; 55(10): 2771 - 2778.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
N. Tiffin, E. Adie, F. Turner, H. G. Brunner, M. A. van Driel, M. Oti, N. Lopez-Bigas, C. Ouzounis, C. Perez-Iratxeta, M. A. Andrade-Navarro, et al.
Computational disease gene identification: a concert of methods prioritizes type 2 diabetes and obesity candidate genes
Nucleic Acids Res., June 6, 2006; 34(10): 3067 - 3081.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. G. Howarth, W. B. Wiehler, M. Pannirselvam, Y. Jiang, J. P. Berger, D. Severson, T. J. Anderson, and C. R. Triggle
A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor {gamma} Agonist Reverses Endothelial Dysfunction in Diabetic (db/db-/-) Mice
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 364 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Pulinilkunnil, D. An, S. Ghosh, D. Qi, G. Kewalramani, G. Yuen, N. Virk, A. Abrahani, and B. Rodrigues
Lysophosphatidic acid-mediated augmentation of cardiomyocyte lipoprotein lipase involves actin cytoskeleton reorganization
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2802 - H2810.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. Apostolova, R. A. S. Schweizer, Z. Balazs, R. M. Kostadinova, and A. Odermatt
Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue
Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E957 - E964.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J. H Steel, R. White, and M. G Parker
Role of the RIP140 corepressor in ovulation and adipose biology
J. Endocrinol., April 1, 2005; 185(1): 1 - 9.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
I. Duivenvoorden, B. Teusink, P. C. Rensen, J. A. Romijn, L. M. Havekes, and P. J. Voshol
Apolipoprotein C3 Deficiency Results in Diet-Induced Obesity and Aggravated Insulin Resistance in Mice
Diabetes, March 1, 2005; 54(3): 664 - 671.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Yu, S. C. Burgess, H. Ge, K. K. Wong, R. H. Nassem, D. J. Garry, A. D. Sherry, C. R. Malloy, J. P. Berger, and C. Li
Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart
PNAS, February 1, 2005; 102(5): 1767 - 1772.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Kabir, K. J. Catalano, S. Ananthnarayan, S. P. Kim, G. W. Van Citters, M. K. Dea, and R. N. Bergman
Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance
Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E454 - E461.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Tu, J. N. Thupari, E.-K. Kim, M. L. Pinn, T. H. Moran, G. V. Ronnett, and F. P. Kuhajda
C75 Alters Central and Peripheral Gene Expression to Reduce Food Intake and Increase Energy Expenditure
Endocrinology, January 1, 2005; 146(1): 486 - 493.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Z. Strowski, Z. Li, D. Szalkowski, X. Shen, X.-M. Guan, S. Juttner, D. E. Moller, and B. B. Zhang
Small-Molecule Insulin Mimetic Reduces Hyperglycemia and Obesity in a Nongenetic Mouse Model of Type 2 Diabetes
Endocrinology, November 1, 2004; 145(11): 5259 - 5268.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Berthiaume, H. Sell, J. Lalonde, Y. Gelinas, A. Tchernof, D. Richard, and Y. Deshaies
Actions of PPAR{gamma} agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1116 - R1123.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. W. Tomlinson, E. A. Walker, I. J. Bujalska, N. Draper, G. G. Lavery, M. S. Cooper, M. Hewison, and P. M. Stewart
11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response
Endocr. Rev., October 1, 2004; 25(5): 831 - 866.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Sell, J. P. Berger, P. Samson, G. Castriota, J. Lalonde, Y. Deshaies, and D. Richard
Peroxisome Proliferator-Activated Receptor {gamma} Agonism Increases the Capacity for Sympathetically Mediated Thermogenesis in Lean and ob/ob Mice
Endocrinology, August 1, 2004; 145(8): 3925 - 3934.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. N. Carley, L. M. Semeniuk, Y. Shimoni, E. Aasum, T. S. Larsen, J. P. Berger, and D. L. Severson
Treatment of type 2 diabetic db/db mice with a novel PPAR{gamma} agonist improves cardiac metabolism but not contractile function
Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E449 - E455.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
K. M. Ogilvie, R. Saladin, T. R. Nagy, M. S. Urcan, R. A. Heyman, and M. D. Leibowitz
Activation of the Retinoid X Receptor Suppresses Appetite in the Rat
Endocrinology, February 1, 2004; 145(2): 565 - 573.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. P. Combs, U. B. Pajvani, A. H. Berg, Y. Lin, L. A. Jelicks, M. Laplante, A. R. Nawrocki, M. W. Rajala, Albert. F. Parlow, L. Cheeseboro, et al.
A Transgenic Mouse with a Deletion in the Collagenous Domain of Adiponectin Displays Elevated Circulating Adiponectin and Improved Insulin Sensitivity
Endocrinology, January 1, 2004; 145(1): 367 - 383.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.